KCM Investment Advisors LLC Sells 2,516 Shares of Johnson & Johnson $JNJ

KCM Investment Advisors LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 1.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 186,280 shares of the company’s stock after selling 2,516 shares during the quarter. Johnson & Johnson accounts for 1.5% of KCM Investment Advisors LLC’s portfolio, making the stock its 16th largest position. KCM Investment Advisors LLC’s holdings in Johnson & Johnson were worth $45,534,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in JNJ. Excelsior Advisor Network LLC lifted its holdings in shares of Johnson & Johnson by 9.6% during the 1st quarter. Excelsior Advisor Network LLC now owns 6,290 shares of the company’s stock valued at $1,537,000 after buying an additional 550 shares during the period. Quantinno Capital Management LP grew its holdings in shares of Johnson & Johnson by 28.2% in the first quarter. Quantinno Capital Management LP now owns 1,608,028 shares of the company’s stock worth $393,066,000 after acquiring an additional 353,259 shares during the period. Lazard Asset Management LLC increased its position in Johnson & Johnson by 44.0% during the first quarter. Lazard Asset Management LLC now owns 1,302,952 shares of the company’s stock valued at $318,494,000 after acquiring an additional 398,406 shares during the last quarter. Cardiff Park Advisors LLC increased its position in Johnson & Johnson by 4.2% during the first quarter. Cardiff Park Advisors LLC now owns 10,601 shares of the company’s stock valued at $2,591,000 after acquiring an additional 426 shares during the last quarter. Finally, Intelligence Driven Advisers LLC bought a new position in Johnson & Johnson in the first quarter valued at about $271,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on JNJ. Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. Argus increased their price objective on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research note on Thursday, April 16th. Daiwa Securities Group raised their price objective on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a report on Thursday, April 16th. Scotiabank restated an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. Finally, Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $263.00 to $272.00 and gave the company an “overweight” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $265.30.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $266.35 on Tuesday. The business has a 50-day simple moving average of $243.46 and a two-hundred day simple moving average of $236.98. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $164.23 and a 52 week high of $269.43. The stock has a market cap of $641.88 billion, a price-to-earnings ratio of 30.86, a PEG ratio of 2.50 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts expect that Johnson & Johnson will post 11.68 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s payout ratio is currently 62.11%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported second-quarter revenue of $25.31 billion, up 6.6% year over year and ahead of analyst expectations. Adjusted EPS of $2.90 also exceeded consensus estimates, while management raised its 2026 earnings outlook to $11.60–$11.75 per share. Johnson & Johnson Raised Its Outlook
• Positive Sentiment: The proposed talc settlement could remove a major source of legal uncertainty for Johnson & Johnson by resolving tens of thousands of ovarian-cancer claims, provided at least 95% of remaining claims participate. The agreement follows a favorable ruling by the federal multidistrict-litigation court. Johnson & Johnson Agrees to Pay Up to $5.5 Billion to Settle Talc Lawsuits

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.